Elevation Oncology, Inc. appointed Joseph J. Ferra, Jr. as Chief Executive Officer of the Company at the Companyâs 2025 Annual Meeting of Stockholders, in each case, effective as of July 12, 2023 (the âFerra Effective Dateâ). Mr. Ferra, age 48, served as the Companyâs Chief Financial Officer since June 2021 and as the Companyâs Interim Chief Executive Officer and President since January 2023. Mr. Ferra joined the Company from Syros Pharmaceuticals, Inc., where he served as Chief Financial Officer from March 2018 to June 2021.
Mr. Ferra received a B.S. in chemistry with distinction from Purdue University and an M.B.A. from The Stephen M. Ross School of Business at the University of Michigan. There are no arrangements or understandings between Mr. Ferra and any other persons, pursuant to which he was appointed as Chief Executive Officer and President, there are no family relationships among any of the Companyâs directors or executive officers and Mr. Ferra, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.